A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

  • End date
    Mar 1, 2023
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 15 September 2021
absolute neutrophil count
gastric adenocarcinoma
pancreatic adenocarcinoma
liver metastasis
esophageal adenocarcinoma
blood transfusion
gallbladder carcinoma
colorectal adenocarcinoma
gastrointestinal cancer
endoscopic procedures


Phase Ia - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period. The MTD evaluation period is defined as the first two treatment cycles (from first dose administration until the day preceding the third dose administration or end of REP in case of discontinuation before start of Cycle 3).

Phase Ia - Explore pharmacokinetics/pharmacodynamics, and efficacy to guide the determination of a potentially effective dose range for phase Ib in the absence of MTD.

Phase Ib - Evaluate efficacy and safety of BI 905711 at a potentially effective dose range and determine the Recommended Phase 2 Dose (RP2D)

Condition Pancreatic Cancer, Gastrointestinal Neoplasm, Adenocarcinoma, Cholangiocarcinoma, Pancreatic disorder, GASTROINTESTINAL DISORDER, Neoplasm of unspecified nature of digestive system, Pancreatic Disorders, Gastrointestinal Diseases and Disorders, Islet Ce417ll Cancer, Malignant Adenoma, Digestive System Neoplasms, pancreatic neoplasm, gastrointestinal tumor, gastrointestinal tract tumor, gastrointestinal tumors, digestive system tumor
Treatment BI 905711
Clinical Study IdentifierNCT04137289
SponsorBoehringer Ingelheim
Last Modified on15 September 2021


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed, advanced unresectable or metastatic gastrointestinal cancers of following histologies
Colorectal adenocarcinoma
Gastric adenocarcinoma
Esophageal adenocarcinoma
Pancreatic adenocarcinoma
Cholangiocarcinoma and gallbladder carcinoma
Small intestine adenocarcinoma
Patient who has failed all available conventional therapies known to confer clinical benefit for their disease based on local approved standards. For patients with colorectal cancer, prior treatment with regorafenib or TAS-102 is optional
Phase Ia (dose escalation) only: Patient with either measurable or non-measurable/non-evaluable disease
Phase Ia (expanded cohort) and Phase Ib (expansion phase) only: At least one target lesion that can be accurately measured per RECIST v.1.1
Adequate hepatic, renal and bone marrow functions as defined by all of the below
Availability and willingness to undergo tumor biopsy before treatment to provide tumor tissue. Pre-treatment fresh tumor biopsy collections for biomarker analyses are considered optional in phase Ia and mandatory in phase Ib. Only non-significant risk procedures per the investigator's judgment will be used to obtain any biopsies specified in this study. In case a fresh tumor biopsy cannot be obtained due to before mentioned reasons an archived tumor tissue specimen needs to be submitted
Total bilirubin 1.5 x institutional Upper Level of Normal (ULN) ( 3 x institutional ULN for patient with Gilbert's syndrome)
ALT and AST 2.5 x institutional ULN (5 x institutional ULN for patients with known liver metastases)
Serum creatinine 1.5x institutional ULN. If creatinine is > 1.5 x ULN, patient is eligible if concurrent creatinine clearance 50 ml/min (>0.05 L/min) (measured or calculated by CKD-EPI formula or Japanese version of CKD-EPI formula for Japanese patients)
ANC 1.0x 10^9/L ( 1.0 x 103/L, 1,000/mm3)
Platelets 100x10^9/ L ( 100 x 103/L, 100 x 103/mm3)
Hb 9.0 g/dl ( 90 g/L, 5.6 mmol/L) (without transfusion within previous week)
Serum lipase 1.5 institutional ULN
Recovery from any adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia CTCAE grade 2, sensory peripheral neuropathy CTCAE grade 2 or considered not clinically significant
Eastern Cooperative Oncology Group (ECOG) performance status 1
Life expectancy 3 months in the opinion of the investigator
Of legal adult age (according to local legislation) at screening
Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly

Exclusion Criteria

Previous systemic anti-cancer therapy within the specified timeframe from the last dose intake to the first dose of trial treatment as shown below
Any non-investigational drug, including anti-angiogenic antibodies (bevacizumab or ramucirumab) and anti-EGFR antibodies (cetuximab or panitumumab), within 14 days
Any investigational drug or other antibodies including immune checkpoint inhibitors, within 28 days
Known pathological condition of GI tract, liver and pancreas, excluding the disease under study, that may interfere with assessment of drug safety or may increase the risk of toxicity
Radiation therapy within 4 weeks prior to start of treatment. However, palliative radiotherapy for symptomatic metastasis is allowed if completed within 2 weeks prior to start of treatment but must be discussed with the sponsor
inflammatory bowel disease
Any serious concomitant disease or medical condition affecting compliance with Trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal (GI) tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator, would make the patient inappropriate for entry into the trial. Any history of stroke or myocardial infarction within 6 months prior to screening
chronic pancreatitis
other serious GI pathological conditions by judgment of the investigator e.g. autoimmune disease with GI involvement, unexplained active diarrhea CTCAE grade 2 according to CTCAE v5.0
Known history of human immunodeficiency virus infection
Any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable if done within 14 days before the informed consent date
Positive results of hepatitis B surface (HBs) antigen
Presence of HBc antibody together with HBV-DNA
Presence of hepatitis C RNA
Active concomitant malignancies, other than the one treated in this trial
Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to comply with the protocol requirements or not expected to complete the trial as scheduled
Women who are pregnant, nursing, or who plan to become pregnant while in the trial; female patients who do not agree to the interruption of breast feeding from the start of study treatment to within 30 days after the last study treatment
Presence of uncontrolled or symptomatic brain or subdural metastases. Inclusion of patients with brain metastases who have completed local therapy and are considered stable by the investigator, or with newly identified asymptomatic brain metastases at screening will be allowed. Use of corticosteroids is allowed if the dose was stable for at least 1 week before the baseline MRI
Patients who are under judicial protection and patients who are legally institutionalized
Major surgery (major according to the investigator's assessment) performed within 3 weeks prior to treatment start or planned within 3 months after screening, e.g. hip replacement
Any of the following cardiac criteria
Resting corrected QT interval (QTc) >470 msec
Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block
Patients with an ejection fraction (EF) <50% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram, multi-gated acquisition scan). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both
Known hypersensitivity to the trial medication and/or its components i.e. polysorbate 20, sodium citrate, lysine hydrochloride, sucrose, citric acid
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note